p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the addition of cyclophosphamide to the
treatment with the p53-SLP vaccine improves clinical efficacy and immunogenicity of the
p53-SLP vaccine in ovarian cancer patients.